Stockscreener 앱 받기
1.985
1.97%
-0.045
Neurosense Therapeutics Ltd 주식(NRSN)의 최신 뉴스
What makes NeuroSense Therapeutics Ltd. Equity Warrant stock price move sharplyTrade Ready Signal - Newser
What makes NeuroSense Therapeutics Ltd. stock price move sharplyMassive Profit Potential - Newser
How NeuroSense Therapeutics Ltd. stock performs during market volatilityProven Trading Plan - Newser
Why NeuroSense Therapeutics Ltd. Equity Warrant stock attracts strong analyst attentionExpert Backed Predictions - Newser
How NeuroSense Therapeutics Ltd. Equity Warrant stock performs during market volatilityGrowth Optimized Stock Radar - Newser
Why NeuroSense Therapeutics Ltd. stock attracts strong analyst attentionHigh Return Intraday Picks - Newser
D. Boral Capital Reaffirms Buy Rating for NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
NeuroSense Therapeutics Releases Q2 2025 Corporate Update - TipRanks
NeuroSense Therapeutics (NASDAQ:NRSN) Trading 0.5% Higher – Here’s What Happened - Defense World
NeuroSense Completes Key Meeting with Health Canada for ALS Drug Approval - TipRanks
NRSN: Health Canada Meeting Advances PrimeC Toward Expedited ALS Approval - Stock Titan
NeuroSense Therapeutics (NRSN) Expected to Announce Earnings on Tuesday - Defense World
Why It Makes Sense To Keep An Eye On NeuroSense Therapeutics - RTTNews
NeuroSense Stock Soars 10.33% on ALS Treatment Commercialization Plans - AInvest
Jane Street Group LLC Makes New Investment in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
Top Nasdaq Companies by Market Cap Ranked by Kalkine - Kalkine Media
NeuroSense Therapeutics (NASDAQ:NRSN) Trading Up 1.2% – Here’s What Happened - Defense World
Citadel Advisors LLC Buys 219,717 Shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) - Defense World
NRSNNeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - mx.advfn.com
NRSN stock touches 52-week high at $1.65 amid robust gains - Investing.com
NRSN stock touches 52-week high at $1.52 amid growth optimism - Investing.com Australia
D. Boral Capital Begins Coverage on NeuroSense Therapeutics (NASDAQ:NRSN) - Defense World
D. Boral Capital Initiates Coverage of NeuroSense Therapeutics (NRSN) with Buy Recommendation - Nasdaq
Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst InsightsNeuroSense Therapeutics (NASDAQ:NRSN) - Benzinga
Boral Capital starts NeuroSense stock with Buy, $14 target By Investing.com - Investing.com South Africa
This NeuroSense Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Monday - Benzinga
NeuroSense (NRSN) Receives Buy Rating with Promising Outlook | N - GuruFocus
Boral Capital starts NeuroSense stock with Buy, $14 target - Investing.com
Amyotrophic Lateral Sclerosis Market Set for Groundbreaking - openPR.com
NeuroSense Completes PrimeC Manufacturing Scale-Up for Canadian Launch - TipRanks
NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch - Nasdaq
NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement - ADVFN
NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND - ADVFN
NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why - Defense World
NeuroSense Therapeutics Advances ALS Treatment and Strategic Partnership - TipRanks
NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - Quantisnow
Head-To-Head Contrast: NeuroSense Therapeutics (NASDAQ:NRSN) versus TFF Pharmaceuticals (NASDAQ:TFFP) - Defense World
NLS and Kadimastem: Swiss-israeli merger in ALS - European Biotechnology Magazine
Neurosense Therapeutics Announces Phase 2B Microrna Data - marketscreener.com
Groundbreaking ALS Treatment Cuts Disease Progression by 33%, Boosts Survival 58% - Stock Titan
NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment - PR Newswire
3.69%
2.49%
자본화:
|
볼륨(24시간):